The Netherlands-based Argenx, a global immunology biotech company, has announced the acquisition of Forte Biosciences (Dallas, Texas, USA), adding the company's lead candidate, FB102, to its growing immunology pipeline. FB102 is a first-in-class anti-CD122 monoclonal antibody designed to target pathogenic T cells and natural killer (NK) cells, offering a new approach for treating autoimmune diseases.
The decision follows encouraging Phase 1b clinical results in vitiligo and celiac disease, providing early clinical proof that targeting CD122 may be an effective strategy. A Phase 2 study in celiac disease is expected to report results later this year.
According to argenx, FB102 complements its existing antibody portfolio by introducing a different mechanism of action alongside programs such as efgartigimod, empasiprubart, adimanebart and ARGX-121. By targeting pathogenic T-cell and NK-cell activity, the antibody could broaden the company's ability to treat autoimmune diseases driven by different immune pathways.
Beyond vitiligo and celiac disease, FB102 is also being explored for alopecia areata and other autoimmune disorders, giving it the potential to become a platform therapy for multiple indications.